"Tardive Dyskinesia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE).
| Descriptor ID |
D000071057
|
| MeSH Number(s) |
C10.228.662.262.500.500 C10.597.350.275.500 C23.888.592.350.275.500
|
| Concept/Terms |
Tardive Dyskinesia- Tardive Dyskinesia
- Dyskinesia, Tardive
- Dyskinesias, Tardive
- Tardive Dyskinesias
- Tardive Dystonia
- Dystonia, Tardive
- Dystonias, Tardive
- Tardive Dystonias
|
Below are MeSH descriptors whose meaning is more general than "Tardive Dyskinesia".
Below are MeSH descriptors whose meaning is more specific than "Tardive Dyskinesia".
This graph shows the total number of publications written about "Tardive Dyskinesia" by people in this website by year, and whether "Tardive Dyskinesia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
| 2020 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tardive Dyskinesia" by people in Profiles.
-
An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders. CNS Drugs. 2024 04; 38(4):239-254.
-
Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial. Curr Neuropharmacol. 2024; 22(14):2443-2452.
-
Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
-
Oromandibular tics associated with Tourette syndrome. J Neurol. 2023 May; 270(5):2591-2596.
-
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
-
Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
-
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 12; 90(12):1317-1323.
-
Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 04; 9(2):59-71.
-
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
-
The nosology of tardive syndromes. J Neurol Sci. 2018 06 15; 389:10-16.